MPR News Chief Meteorologist Paul Huttner signs off

MPR News helps you turn down the noise and build shared understanding. Turn up your support for this public resource and keep trusted journalism accessible to all. 

Turn Up Your Support

A memo from congressional investigators sheds new light on the inner workings of Martin Shkreli's Turing Pharmaceuticals after the company jacked up the prices of a decades-old drug used to treat AIDS patients.

The House Committee on Oversight and Investigations is looking into Turing and other drug companies' price increases. This memo, released Tuesday, includes excerpts from the company's internal documents and emails.

It paints a picture of the now-disgraced "pharma bro" Martin Shkreli giddily rubbing his palms together at the prospect of all the money Daraprim will generate for his fledgling company. The drug is the only cure for toxoplasmosis, a disease that strikes people, including AIDS and cancer patients, whose immune systems are suppressed.

Turing bought Daraprim last year and jacked up the price 5,000 percent, from $13.50 to $750 a pill.

Here are a few highlights from the data dump.

When Turing agreed to buy Daraprim, company officials went into celebration mode:

The company thought it could handle blowback from AIDS activists and doctors, which it addressed in these presentations:

So Turing went into crisis mode, trying out discount programs and struggling with PR:

 related to his tenure at another firm. He resigned the following day.
"I am confident I will prevail," Shkreli 

Business and Economic News

Health

Alison Kodjak

Author

Congressional investigators have pried loose emails showing how the company's executives anticipated huge profits from a 5,000 percent drug price increase. They were blindsided by the blowback.

A peek inside Martin Shkreli's Turing Pharmaceuticals

Go Deeper.

Like this?

News you can use in your inbox